In this article, we focus on cancer and other human diseases that are linked to abnormal expression and/or function of histone deacetylases (HDACs), the development of HDAC inhibitors and our ...

HDACs in cancer and a (weak) rationale for the development of HDAC inhibitors Overexpression of HDACs has been proposed in several cases as a negative prognostic marker, independently of tumour ...

As a result, increased PD-L1 expression by cancer cells remains a fundamental escape mechanism from host immunity within the tumor microenvironment, and the understanding the molecular mechanisms ...

Specifically, the study showed that the experimental HDAC inhibitor OKI-179 (provided by OnKure Therapeutics, Inc. and currently in a phase 1 clinical trial at CU Cancer Center) was like a switch ...

Lymphomas belong to the group of malignant diseases of the immune system and mainly affect the organs of the lymphatic system ...

Cancer can develop when epigenetic changes ... inhibitors and histone deacetylase (HDAC) inhibitors. These drugs show promise for some cancers, but the ones available now don’t seem to work ...

Chromatin is one of the earliest identified targets for cancer therapeutics ... each variably inhibited by available HDAC inhibitors. The term histone deacetylase is in fact a misnomer in that ...

Growth is driven by increasing epigenetic research influenced by clinical evidence linking epigenetics to various diseases.

Lymphomas belong to the group of malignant diseases of the immune system and mainly affect the organs of the lymphatic system ...

A drug with a past life as a potential anti-cancer agent might someday have ... Institute explained how they discovered that an oral HDAC inhibitor called entinostat acts like an “off-on ...

HDACs are proteins associated with tumor growth and cancer metastasis, with characteristic overexpression in solid tumors. Several HDAC-inhibitor drugs are already FDA-approved (safe for human use ...

Researchers from Northeast Normal University in Changchun demonstrated that compound AW-01178 reversed the abnormal regulation of E-cadherin by inhibiting the class I HDAC enzyme. HDAC inhibitor ...